# Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

> **NCT01123473** · PHASE2 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 29 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Gastric Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** lapatinib ditosylate

## Key facts

- **NCT ID:** NCT01123473
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-08
- **Final completion:** 2014-09
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** company withdrew interest
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123473, "Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01123473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*